Increased Frequency of AlloStim® Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer

Status:   Recruiting

Code: ITL-019-CORK-CRYVAC

Type: Phase II Dose Frequency Escalation

Experimental Product: CryoVax®

Indication: Metastatic Colorectal Cancer

Principal Investigator: Madappa Kundranda, MD, PhD

Location: Banner MD Anderson Medical Center (Phoenix)

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more